(Q36968140)

17 August 2017

1 reference

title

Clinical pharmacology of antifungal agents in pediatric patients (English)

1 reference

17 August 2017

1 reference

2

Thomas J Walsh

1 reference

17 August 2017

Christine C Chiou

1

1 reference

17 August 2017

Andreas H Groll

series ordinal

3

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

15

1 reference

17 August 2017

page(s)

2465-2489

1 reference

Amphotericin B: current understanding of mechanisms of action

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Uncommon opportunistic fungi: new nosocomial threats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Lack of evidence of amphotericin B toxicity in very low birth weight infants treated for systemic candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Amphotericin B nephrotoxicity in humans decreased by salt repletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Prevention of amphotericin-B-induced nephrotoxicity by loading with sodium chloride: a report of 1291 days of treatment with amphotericin B without renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Effects of fluid and electrolyte management on amphotericin B-induced nephrotoxicity among extremely low birth weight infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Clinical pharmacology of antifungal compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Newer systemic antifungal agents : pharmacokinetics, safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Use of amphotericin B colloidal dispersion in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Amphotericin B lipid complex in pediatric patients with invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Population pharmacokinetics of amphotericin B lipid complex in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Liposomal amphotericin (AmBisome) is safe in bone marrow transplantation for primary immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Tolerance of high doses of amphotericin B by infusion of a liposomal formulation in children with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Triad of Acute Infusion‐Related Reactions Associated with Liposomal Amphotericin B: Analysis of Clinical and Epidemiological Characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Diagnosis and management of fungal infections and pneumocystis pneumonitis in pediatric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Oral azole drugs as systemic antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Fluconazole versus ketoconazole in the treatment of oropharyngeal candidiasis in HIV-infected children. Multicentre Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Treatment of oropharyngeal candidiasis in HIV-infected children with oral fluconazole. Multicentre Study Group [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

The treatment of systemic candidiasis in neonates with oral fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Prospective study of fluconazole therapy in systemic neonatal fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Hepatosplenic candidiasis: successful treatment with fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Fluconazole prophylaxis against fungal colonization and infection in preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Treatment of invasive aspergillosis with itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Improved outcome in central nervous system aspergillosis, using voriconazole treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Posaconazole: clinical pharmacology and potential for management of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Disposition of posaconazole following single-dose oral administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Safety and tolerability of caspofungin acetate in the treatment of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Experience with caspofungin in the treatment of persistent fungemia in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2465

10.1517/14656566.8.15.2465

21 January 2018

Identifiers

DOI

1 reference

release_cbbe2r2zireejgo62lkqgutnd4

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cbbe2r2zireejgo62lkqgutnd4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference